General pharmacology of a Pseudomonas vaccine prepared from outer-membrane fractions of Pseudomonas aeruginosa.
CFC-101 is a novel Pseudomonas vaccine with high effectiveness against Pseudomonas infection and is currently under clinical evaluation. The general pharmacological properties of this vaccine were evaluated in mice, rats, guinea pig ileum, and dogs. In vivo doses of 0.2, 2.0 and 20 mg/kg given by intramuscular route, or in vitro concentrations up to 50 micrograms/ml were used. Intramuscular administration of CFC-101 vaccine had no effect on the central nervous system except that the body temperature of rats was slightly decreased at the highest dose, 20 mg/kg. CFC-101 vaccine did not affect the function of smooth muscles, gastrointestinal system, and cardiovascular and respiratory systems. In water and electrolytes excretion test, a decrease in urine output and an elevation of the excretion of Na+, Cl- and total protein at the highest dose (20 mg/kg) were observed. In summary, CFC-101 vaccine had no pharmacological effect in these studies even up to the 100-fold clinical dose, 2 mg/kg.